TY - JOUR
T1 - Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy with Intra-Operative Radiotherapy for Patients with Locally Advanced or Locally Recurrent Rectal Cancer and Peritoneal Metastases
AU - van de Vlasakker, Vincent C.J.
AU - van den Heuvel, Teun B.M.
AU - Rijken, Anouk
AU - Nienhuijs, Simon W.
AU - Ketelaers, Stijn H.J.
AU - Verrijssen, An Sofie E.
AU - Rutten, Harm J.
AU - Nieuwenhuijzen, Grard A.P.
AU - Burger, Jacobus W.A.
AU - de Hingh, Ignace H.J.T.
PY - 2023/2
Y1 - 2023/2
N2 - Purpose: To assess the safety and long-term outcome of a multimodality treatment consisting of radical surgery, intra-operative radiotherapy (IORT), and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for patients with locally advanced rectal cancer (LARC) or locally recurrent rectal carcinoma (LRRC) and peritoneal metastases (PM). Methods: The present study was a single-center cohort study, including all consecutive patients undergoing this treatment in a tertiary referral center for LARC, LRRC, and PM. Postoperative complications, intensive care stay (ICU stay), and re-admission rates were assessed as well as disease-free survival (DFS) and overall survival (OS). Results: A total of 14 LARC and 16 LRRC patients with PM were included in the study. The median ICU stay was 1 day, and 57% of patients developed a severe postoperative complication. No 90-day mortality was observed. Median DFS was 10.0 months (Interquartile Range 7.1–38.7), and median OS was 31.0 months (Interquartile Range 15.9–144.3). Conclusions: As postoperative complications and survival were in line with treatments that are accepted for LARC or LRRC and PM as separate procedures, we conclude that combined treatment with IORT and CRS-HIPEC should be considered as a treatment option for selected patients with LARC or LRRC and peritoneal metastases in tertiary referral centers.
AB - Purpose: To assess the safety and long-term outcome of a multimodality treatment consisting of radical surgery, intra-operative radiotherapy (IORT), and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for patients with locally advanced rectal cancer (LARC) or locally recurrent rectal carcinoma (LRRC) and peritoneal metastases (PM). Methods: The present study was a single-center cohort study, including all consecutive patients undergoing this treatment in a tertiary referral center for LARC, LRRC, and PM. Postoperative complications, intensive care stay (ICU stay), and re-admission rates were assessed as well as disease-free survival (DFS) and overall survival (OS). Results: A total of 14 LARC and 16 LRRC patients with PM were included in the study. The median ICU stay was 1 day, and 57% of patients developed a severe postoperative complication. No 90-day mortality was observed. Median DFS was 10.0 months (Interquartile Range 7.1–38.7), and median OS was 31.0 months (Interquartile Range 15.9–144.3). Conclusions: As postoperative complications and survival were in line with treatments that are accepted for LARC or LRRC and PM as separate procedures, we conclude that combined treatment with IORT and CRS-HIPEC should be considered as a treatment option for selected patients with LARC or LRRC and peritoneal metastases in tertiary referral centers.
KW - colorectal neoplasms
KW - CRS-HIPEC
KW - cytoreduction
KW - intro operative radiotherapy
KW - IORT
KW - LARC
KW - locally advanced rectal cancer
KW - locally recurrent rectal cancer
KW - LRRC
KW - peritoneal metastases
KW - surgical procedures
UR - http://www.scopus.com/inward/record.url?scp=85147766866&partnerID=8YFLogxK
U2 - 10.3390/cancers15030858
DO - 10.3390/cancers15030858
M3 - Article
C2 - 36765814
AN - SCOPUS:85147766866
SN - 2072-6694
VL - 15
JO - Cancers
JF - Cancers
IS - 3
M1 - 858
ER -